Orders from 100 GBP Free delivery from 205 GBP Ready for pickup dead drop: collect in 5 min

Substances · Benzodiazepines and thienodiazepines

Desalkylgidazepam

C17H13ClN4 CAS 28981-97-7 Analytical reference material — not for human consumption
Preferred name
Desalkylgidazepam
IUPAC name
8-chloro-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
Parent CAS number (reference)
28981-97-7
Molecular formula
C17H13ClN4
Molecular weight
308.8 g/mol
InChIKey
VREFGVBLTWBCJP-UHFFFAOYSA-N
PubChem
CID 2118
Source
PubChem
Verified synonyms & catalog abbreviations
Bromonordiazepam Gidazepam M1

Matching Listings in This Store's Catalog

Verified Neurochemical & Toxicological Intelligence

Desalkylgidazepam

Daytime-Leaning Anxiolytic Metabolite (Desalkylgidazepam) 1,4-Benzodiazepine
Verified PubChem & CAS Identity C17H13ClN4 · CAS 28981-97-7 · CID 2118
Calibrated Physical Form Precision Tablets · 1 Tablet = 1 mg
≥98% Analytical Purity Verified 308.8 g/mol
Peer-Reviewed & Agency Citations 2 · verified sources

Receptor Telemetry & Mechanism of Action

GABAₐ α₂/α₃ Anxiolysis & Myorelaxation High PAM
GABAₐ α₁ Hypnotic / Sedative Drive Moderate-High
GABAₐ α₅ Amnestic / Cognitive Modulation Moderate

Active N-desalkyl metabolite of gidazepam (bromonordiazepam) acting as a partial/selective GABA-A modulator with lower hypnotic sedation than triazolobenzodiazepines.

Biotransformation & Active Metabolites

Slow hepatic elimination with an extended ~80-hour plasma half-life.

Temporal Pharmacokinetics

Daytime-Leaning Anxiolytic Metabolite (Desalkylgidazepam) — Mild per-milligram potency (1 tablet = 1 mg; common literature range 3–6 mg) with gentle anxiolysis and long elimination half-life (~80 h).

  1. Onset 30–75 min
  2. Peak Window 2–4 h
  3. Total Window 8–14 h
  4. Residual / Half-Life 24–60 h residual (T1/2 ~80 h)

Mild per-milligram potency (1 tablet = 1 mg; common literature range 3–6 mg) with gentle anxiolysis and long elimination half-life (~80 h).

Quantitative Response Spectrum (Published Literature)

Third-person observational & toxicological brackets reported in scientific and harm-reduction literature — reference telemetry only, never consumption advice.

Threshold
1–2 mg
Cognitive & Sensory

Subtle threshold receptor activity (Daytime-Leaning Anxiolytic Metabolite (Desalkylgidazepam)).

Somatic & Autonomic

Minimal baseline autonomic shift.

Light
2–3 mg
Cognitive & Sensory

Mild, clear-headed expression of primary class profile.

Somatic & Autonomic

Light somatic modulation.

Common Reference
3–6 mg
Cognitive & Sensory

Full characteristic neurochemical and perceptual profile documented in literature.

Somatic & Autonomic

Moderate somatic relaxation, ataxia, or autonomic tone depending on class.

Strong
6–9 mg
Cognitive & Sensory

Pronounced intensity, cognitive/motor impairment, or deep immersion.

Somatic & Autonomic

Marked somatic load and heightened adverse-event sensitivity.

Heavy / Toxic Zone
12+ mg
Cognitive & Sensory

Amnesia, blackout, acute dysphoria, confusion, or anesthetic dissociation.

Somatic & Autonomic

High toxicity zone: severe motor loss, cardiovascular strain, or respiratory hazard.

Interaction Matrix & Critical Contraindications

Critical Hazard — Never Combine

Opioids (O-DSMT, tramadol, morphine, oxycodone, fentanyl)

Synergistic brainstem respiratory depression causing unconsciousness and fatal respiratory arrest.

Alcohol, GHB/GBL, and Barbiturates

Extreme CNS depression, complete anterograde amnesia, loss of airway reflexes, and fatal aspiration.

Elevated Hazard — Avoid

Dissociatives (Ketamine, 2-FDCK, DCK, O-PCE, MXE)

Unpredictable sedation, severe motor ataxia, blackout, and emesis aspiration hazard.

Caution / Receptor Attenuation

CYP3A4 inhibitors (grapefruit juice, ketoconazole) & Stimulants

CYP3A4 inhibitors prolong plasma half-life; stimulants mask sedation until they wear off.

Structural Isomer & Sibling Comparison

Mild per-milligram potency (1 tablet = 1 mg; common literature range 3–6 mg) with gentle anxiolysis and long elimination half-life (~80 h).

Physicochemical Stability & Storage

Form: Precision-pressed 1 mg analytical tablets (1 tablet = 1 mg). · Parent molecule soluble in ethanol, propylene glycol, and DMSO; sparingly soluble in water.

Store sealed in a cool, dry, light-protected container away from humidity.

Cross-Tolerance & Dependence Profile

Complete cross-tolerance across all GABA-A benzodiazepines/thienodiazepines. Rapid physical dependence develops with continuous daily exposure; abrupt cessation after prolonged intake can trigger life-threatening rebound seizures and delirium.

Comprehensive Analytical & Toxicological Monograph

Desalkylgidazepam (8-chloro-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine; CAS 28981-97-7, PubChem CID 2118) is a 1,4-benzodiazepine reference compound (C17H13ClN4, 308.8 g/mol) classified pharmacologically as a Daytime-Leaning Anxiolytic Metabolite (Desalkylgidazepam). Active N-desalkyl metabolite of gidazepam (bromonordiazepam) acting as a partial/selective GABA-A modulator with lower hypnotic sedation than triazolobenzodiazepines. Slow hepatic elimination with an extended ~80-hour plasma half-life. In published observational and toxicological literature, threshold response is noted at 1–2 mg, light range at 2–3 mg, common reference range at 3–6 mg, strong intensity at 6–9 mg, and heavy/adverse territory at 12+ mg, with an onset of 30–75 min, peak window of 2–4 h, and total duration of 8–14 h (24–60 h residual (T1/2 ~80 h)). Mild per-milligram potency (1 tablet = 1 mg; common literature range 3–6 mg) with gentle anxiolysis and long elimination half-life (~80 h). Critical contraindications include Opioids (O-DSMT, tramadol, morphine, oxycodone, fentanyl), Alcohol, GHB/GBL, and Barbiturates.

Chemical Architecture & Structural Profile

Desalkylgidazepam (8-chloro-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine) is a reference compound belonging to the Benzodiazepines and thienodiazepines class, characterized by the molecular formula C17H13ClN4 and a molar mass of 308.8 g/mol. The parent molecule is indexed under CAS registry number 28981-97-7 and in the NCBI PubChem database as CID 2118 (Standard InChIKey: VREFGVBLTWBCJP-UHFFFAOYSA-N).

Citations

Reference Toxicology & Safety Profile

In documented chemical and harm-reduction literature (PubChem / PsychonautWiki, CC BY 4.0), Desalkylgidazepam is indexed within the Benzodiazepines and thienodiazepines structural group. Triazolo/thienodiazepine reference compound; carries a high risk of synergistic respiratory depression if combined with opioids, alcohol, or other CNS depressants. Standard laboratory handling precautions—including nitrile gloves, eye protection, and local exhaust ventilation—apply whenever handling the reference material.

Citations

Analytical Use & Laboratory Notice

This reference sheet provides chemical, analytical, and toxicological provenance only. The material is strictly not for human consumption, diagnostic, or veterinary use. Research-use labelling does not establish legal status in any jurisdiction.

Citations